Pacer Advisors
SWTX

Pacer Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Pacer Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-887
Closed -$33.4K – 2691
2024
Q2 		$33.4K Buy
887
+53
+6% +$2.23K ﹤0.01% 3318
2024
Q1 		$41K Buy
+834
New +$38.6K ﹤0.01% 3251
2021
Q2 		– Sell
-988
Closed -$73K – 1551
2021
Q1 		$73K Sell
988
-322
-25% -$25.2K ﹤0.01% 1357
2020
Q4 		$95K Buy
+1,310
New +$84.3K ﹤0.01% 1373

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Pacer Advisors's SWTX Position: Q3 2024 in Review

Pacer Advisors sold out of SpringWorks Therapeutics (SWTX) in Q3 2024, closing a stake of 887 shares — an estimated $33.4K sold.

Pacer Advisors first reported a position in SWTX in Q4 2020 and held it in 4 quarters. The position peaked at $95K in Q4 2020. 226 funds tracked by Wall St. Rank hold SWTX as of Q3 2024.

  • Pacer Advisors reported no remaining SpringWorks Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 887 SpringWorks Therapeutics shares in Q3 2024, an estimated $33.4K.
  • Pacer Advisors first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's SpringWorks Therapeutics position peaked at $95K in Q4 2020.
  • 226 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.